Added to YB: 2025-11-05
Pitch date: 2025-10-31
GSK [bullish]
GSK plc
+3.26%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 72.9B
Pitch Price
GBP 17.67
Price Target
N/A
Dividend
3.36%
EV/EBITDA
8.93
P/E
13.65
EV/Sales
2.70
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 31/10/2025 - GSK – Positive Q3, guidance raised
GSK (update): Strong Q3 w/ +7% revenue growth, guidance raised to 6-7% turnover & 10-12% core EPS growth. 15 pipeline opportunities >£2bn peak sales launching 2025-31. Trades 9.9x 2026 consensus earnings, 3.9% yield. Net debt 1.3x 2025 EBITDA. Undemanding multiple vs strong momentum.
Read full article (2 min)